, Volume 113, Issue 1, pp 76–82 | Cite as

Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers

  • Emmanuel Mignot
  • Alain Renaud
  • Seiji Nishino
  • Janis Arrigoni
  • Christian Guilleminault
  • William C. Dement
Original Investigations


Narcolepsy is currently treated with antidepressants to control REM-related symptoms such as cataplexy and with amphetamine-like stimulants for the management of sleepiness. Both stimulant and antidepressant drugs presynaptically enhance monoaminergic transmission but both classes of compounds lack pharmacological specificity. In order to determine which monoamine is selectively involved in the therapeutic effect of these compounds, we examined the effects of selective monoamine uptake inhibitors and release enhancers on cataplexy using a canine model of the human disorder. A total of 14 compounds acting on the adrenergic (desipramine, nisoxetine, nortriptyline, tomoxetine, viloxazine), serotoninergic (fenfluramine, fluoxetine, indalpine, paroxetine, zimelidine) and dopaminergic (amfonelic acid, amineptine, bupropion, GBR 12909) systems were tested. Some additional compounds interesting clinically but with less pharmacological selectivity, i.e., cocaine, dextroamphetamine, methylphenidate, nomifensine and pemoline, were also included in the study. All compounds affecting noradrenergic transmission completely suppressed canine cataplexy at low doses in all dogs tested, whereas compounds which predominantly modified serotoninergic and dopaminergic transmission were either inactive or partially active at high doses. Our results demonstrate the preferential involvement of adrenergic systems in the control of cataplexy and, presumably, REM sleep atonia. Our findings also demonstrate that canine narcolepsy is a useful tool in assessing the pharmacological specificity of antidepressant drugs.

Key words

Narcolepsy Cataplexy Uptake inhibition Antidepressant REM sleep Noradrenaline Serotonin Dopamine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aldrich M(1992) Narcolepsy. Neurology 42:34–43Google Scholar
  2. Andersen PH (1989) The dopamine uptake inhibitor. GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 166:493–504Google Scholar
  3. Appel NM, Mitchell WMM, Contrera JF, De Souza EB (1990) Effects of high dose fenfluramine treatment on monoamine uptake sites in rat brain: assessment using quantitative autoradiography. Synapse 6:33–44Google Scholar
  4. Babcock DA, Narver EL, Dement WC, Mitler MM (1976) Effects of imipramine, chlorimipramine, and fluoxetine on cataplexy in dogs. Pharmacol Biochem Behav 5:599–602.Google Scholar
  5. Baker T, Dement WC (1985) Canine narcolepsy-cataplexy syndrome; evidence for an inherited monoaminergic-cholinergic imbalance. In: DJ McGinty, Drucker-Collin R, Morrison A, Parmeggiani P (eds) Brain mechanisms of sleep. Raven, New York, pp 199–233Google Scholar
  6. Bertilsson L, Tuck JR, Siwers B (1980) Biochemical effects of Zimelidine in man. Eur J Pharmacol 18:483–487Google Scholar
  7. Brogden RN, Heel RC, Speight TM, Avery GS (1979) Nomifensine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 18:1–24Google Scholar
  8. Buus Lassen J, Squires F, Christensen JA, Molander L (1975) Neurochemical and pharmacological studies on a new 5-HT uptake inhibitor, FG 4963, with potential antidepressant properties. Psychopharmacology 42:21–26Google Scholar
  9. Cadilhac J (1976) Tricyclic and REM sleep. In: Guilleminault C, Passouant P, Dement WC (eds) Narcolepsy. Spectrum, New York, pp 605–623Google Scholar
  10. Chouinard G, Annabel L, Bradwejn J (1984) An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacology 83:126–128Google Scholar
  11. Ferris RM, Beaman OJ (1983) Bupropion; a new antidepressant drug, the mechanism of action of which is not associated with down regulation of postsynaptic beta-adrenergic, serotoninergic (5-HT2), alpha-2 adrenergic, imipramine and dopaminergic receptors in the brain. Neuropharmacology 22[11] 1257–1983Google Scholar
  12. Fuller RW, Snoddy HD, Molloy BB (1975) Blockade of amine depletion by nisoxetine in comparison to other uptake inhibitors. Psychopharmacol Commun 1[5]:455–464Google Scholar
  13. Gaillard JM, Kafi S (1979) Involvement of pre- and postsynaptic receptors in catecholaminergic control of paradoxical sleep in man. Eur J Clin Pharmacol 15:83–89Google Scholar
  14. Garattini S, Mennini T (1988) Critical notes on the specificity of drugs in the study of metabolism and functions of brain monoamines. Inter Rev Neurobiol 29:259–280Google Scholar
  15. Garattini S, Mennini T (1989) Pharmacology of amineptine: synthesis and update. Clin. Neuropharmacol (Suppl 2) 12:S13-S18Google Scholar
  16. Glowinski J, Axelrod J (1964) Inhibition of uptake of tritiated noradrenaline in intact brain by imipramine and structurally related compounds. Nature, 204:1318–1320Google Scholar
  17. Guilleminault C, Mancuso J, Quera Salva MA, Hayes B, Mitler M, Poirier G. Montplaisir J (1986) Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep 9 [1] 275–279Google Scholar
  18. Heikkila RE, Manzino L (1984) Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: Specific inhibitors of dopamine uptake. Eur J Pharmacol 103:241–248Google Scholar
  19. Hishikawa Y, Ida H, Nakai K, Kaneko Z (1966) Treatment of narcolepsy with imipramine and desmethylimipramine. J Neurol Sci 3:453–459Google Scholar
  20. Johnson AM (1989) An overview of the animal pharmacology of paroxetine. Acta Psychiatr Scand Suppl 350:14–20Google Scholar
  21. Kafi-De St Hilaire S, Merica H, Gaillard JM (1984) The effects of indalpine — a selective inhibitor of 5-HTuptake — on rat paradoxical sleep. Eur J Pharmacol 98:413–418Google Scholar
  22. Karczmar AG, Longo VG, Scotti de Carolis A (1970) A pharmacological model of paradoxical sleep: The role of cholinergic and monoaminergic systems. Physiol Behav 5:175–182.Google Scholar
  23. Kuhar MJ, Ritz MC, Boja JW (1991) The dopamine hypothesis of the reinforcing properties of cocaine. TIPS 14[7]:299–302Google Scholar
  24. Langdon N, Shindler J, Parkes JD, Bandak S (1986) Fluoxetine in the treatment of cataplexy. Sleep 9[2]:371–373Google Scholar
  25. Lefur G, Uzan A (1977) Effects of 4-(3-indolylalkyl) piperidine derivatives on uptake and release of noradrenaline, dopamine and 5-hydroxytryptamine in rat brain synaptosomes, rat heart and human blood platelets. Biochem Pharmacol 26:497–503Google Scholar
  26. McMillen BA (1983) CNS stimulants: Two distinct mechanisms of action for amphetamine-like drugs. TIPS 10:429–432Google Scholar
  27. McMillen BA, Scott SM, Williams HL (1991) Effects of subchronic amphetamine or amfonelic acid on rat brain dopaminergic and serotoninergic function. J. Neural Transm [GenSect] 83:55–66Google Scholar
  28. McTavish D, Hell RC (1992) Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs 43[5]:713–733Google Scholar
  29. Mignot E, Guilleminault C, Bowersox S, Rappaport A, Dement WC (1988) A role of central alpha 1 adrenoceptors in canine narcolepsy. J Clin Invest 82:885–894Google Scholar
  30. Mignot E, Guilleminault C, Dement WC, Grumet C (1992) Genetically determined animal models of narcolepsy, a disorder of REM sleep. In: Driscoll D (ed) Genetically determined animal models of neurobehavioral dysfunction. Birkhauser Boston Cambridge, pp 90–110Google Scholar
  31. Mignot E, Nishino S, Hunt-Sharp L, Arrigoni J, Siegel JM, Reid MS, Edgar D, Ciaranello RD, Dement WC (1993) Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymtomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. J Neurosci 13[3]:1057–1064Google Scholar
  32. Mitler MM, Hadjucovic R (1991) Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep 14:218–220Google Scholar
  33. Montplaisir J, Godbout R (1986) Serotoninergic reuptake mechanisms in the control of cataplexy. Sleep 9[1]:280–284Google Scholar
  34. Monti JM (1983) Minireview: catecholamines and the sleep wake cycle. Life Sci 32:1401–1415Google Scholar
  35. Nicholson AN, Pascoe PA (1988) Studies on the modulation of the sleep-wakefulness continuum in man by fluoxetine, a 5-HT uptake inhibitor. Neuropharmacol, 27[6]:597–602Google Scholar
  36. Nicholson AN, Pascoe PA (1986) 5-Hydroxytryptamine and noradrenaline uptake inhibition: studies on sleep in man. Neuropharmacology 25[10]:1079–1083Google Scholar
  37. Nicholson AN, Pascoe PA (1990) Dopaminergic transmission and the sleep-wakefulness continuum in man. Neuropharmacology 29[4]:411–417Google Scholar
  38. Nishino S, Haak L, Shepperd H, Guilleminault C, Sakai T, Dement WC, Mignot E (1990) Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of REM sleep. J Pharmacol Exp Ther 253[3]:1145–1152Google Scholar
  39. Nishino S, Arrigoni J, Valtier D, Miller J, Guilleminault, C, Dement WC, Mignot E (1991) Involvement of dopamine D2-type receptors in the regulation of cataplexy in canine narcolepsy. J Neurosci 11:2666–2671Google Scholar
  40. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC (1990) In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse 6:106–112Google Scholar
  41. Ogren SO, Ross SB, Hall H, Holm AC, Renyi AL (1981) The pharmacology of zimelidine: A 5-HT selective reuptake inhibitor Acta Psychiatr Scand Suppl 290 [63]:127–151Google Scholar
  42. Parkes D (1976) Amphetamine and alertness. In: Guilleminault C, Passouant P, Dement WC (eds) Narcolepsy. Spectrum New York pp 643–658Google Scholar
  43. Pinder RM, Brodgen RN, Speight TM, Avery GS (1977) Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 13:401–421Google Scholar
  44. Pliska V (1987) Dose-response models: similarity with population growth dynamics. TIPS 8:50–52Google Scholar
  45. Polc P, Schneeberger J, Haefely W (1979) Effects of several centrally active drugs on the sleep-wakefulness cycle in cats. Neuropharmacology 18:259–265Google Scholar
  46. Richelson E (1984) The newer antidepressants: structures, pharmacokinetics, pharmacodynamics and proposed mechanisms of action. Psychopharmacol Bull 20[2]:213–223Google Scholar
  47. Richelson E. Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104:277–186Google Scholar
  48. Ross RJ, Ball WA, Gresch PJ, Morrison AR (1990) REM sleep suppression by monoamine reuptake blockade: development of tolerance with repeated drug administration. Biol Psychiatry 28:231–239Google Scholar
  49. Rudorfer MV, Potter WZ (1989) Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the newer versus the older drugs. Drugs 37:713–738Google Scholar
  50. Saletu B, Frey R, Kruptka M, Anderer P, Grunberger J, See WR (1991) Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 14[5]:439–447Google Scholar
  51. Schachter M, Parkes JD (1980) Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry 43:171–174Google Scholar
  52. Schrader H, Kayed K, Bendixen Markset B, Treidene HE (1986) The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand 74:297–303Google Scholar
  53. Siegel JM (1989) Brainstem mechanisms generating REM sleep. In: Kryger MH, Roth T, Dement WC (eds) Principles and practice of sleep medicine. Saunders, Philadelphia, pp 104–120Google Scholar
  54. Sommi RW, Crismon ML, Bowden CL (1987) Fluoxetine: a serotonin-specific, second-generation antidepressant. Pharmacotherapy 7 [1]:001–015Google Scholar
  55. Soroko FE, Mehta NB, Maxwell RA, Ferris RM, Schroeder DH (1977) Bupropion hydrochloride [(±) alpha-t-butylamino-3-chloropiophenone HCl]: a novel antidepressant agent. J Pharm Pharmacol 29:767–770Google Scholar
  56. Steriade M, McCarley R (eds) (1990) Brainstem control of wakefulness and sleep. Plenum, New YorkGoogle Scholar
  57. Tejani-Butt SM, Brunswick DJ, Frazer A (1990) [3H]-Nisoxetine: a new radioligand for norepinephrine uptake sites in brain. Eur J Pharmacol 191:239–243Google Scholar
  58. Tulloch IA, Johnson AM (1992) The pharmacological profile of paroxetine, a new selective serotonin reuptake inhibitor. J Clin Psychiatry (suppl) 53[2]:7–12Google Scholar
  59. Waldmeier PC (1982) Effects of antidepressant drugs on dopamine uptake and metabolism. J Pharm Pharmacol 34:391–394Google Scholar
  60. Wong DT, Bymaster FP, Reid LR, Threlkeld PG (1983) Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol 32[7]:1287–1293Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Emmanuel Mignot
    • 1
  • Alain Renaud
    • 1
  • Seiji Nishino
    • 1
  • Janis Arrigoni
    • 1
  • Christian Guilleminault
    • 1
  • William C. Dement
    • 1
  1. 1.School of Medicine, Sleep Disorders CenterStanford UniversityPalo AltoUSA

Personalised recommendations